TEL AVIV, Israel , Nov. 21, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that data on the new investigator-sponsored Phase 2 study of VB-111 in recurrent glioblastoma (rGBM) will be presented by Timothy Cloughesy , M.D., Director and Professor, UCLA Neuro-Oncology...

Conference Call and Webcast at 8:30am Eastern Time Today TEL AVIV, Israel , Nov. 14, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the third quarter ended September 30, 2019 , and provided a corporate update....

Trial will be conducted at top neuro-oncology US centers, further exploring the potential of VB-111 in recurrent glioblastoma (rGBM) which is an immunologically `cold` tumor TEL AVIV, Israel , Nov. 06, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that an investigational...

TEL AVIV, Israel , Oct. 31, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio...

Conference Call and Webcast at 8:30am Eastern Time Today TEL AVIV, Israel , Aug. 13, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the second quarter ended June 30, 2019 , and provided a corporate update....

TEL AVIV, Israel , Aug. 05, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio...

TEL AVIV, Israel , July 22, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that its new gene therapy manufacturing facility in...

TEL AVIV, Israel , June 04, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:  VBLT ), announced that Dr. Dror Harats , CEO will deliver a company presentation today at the 2019 BIO International Convention in Philadelphia. The presentation will include a discussion on the recent VB-111 progress,...

TEL AVIV, Israel , June 03, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that MRI data from VB-111 Phase 2 and Phase 3 studies in recurrent GBM (rGBM), presented yesterday at the 2019 American Society of Clinical Oncology ( ASCO ) annual meeting, showed a survival...

VB-111 demonstrated a statistically significant increase in overall survival at therapeutic vs. low dose (498 days vs. 172.5 days, p=0.03) CA-125 response (GCIG) was reported in 58% of evaluable patients and was predictive of overall survival, in patients treated with a therapeutic dose of VB-111...